Telmisartan Market Latest Trends By Market Analysis with Top Players Medtronic, General Electric, C. R. Bard, ConvaTec. Smith Medical, KindWell Medical

Availability of better treatment options for hypertension has lead substantial portion of the hypertensive population with controlled blood pressure. But rising population with cardiovascular, and associated disorders urges need for different antihypertensive drugs in the global market. Telmisartan is a non-peptide angiotensin receptor blocker intended for treatment of hypertension and other cardiovascular disorders. Telmisartan was approved by the US Food and Drug Administration (USFDA) in 1998, for the treatment of hypertension alone or in combination with other compounds.

The global telmisartan market size was valued at US$ 3,880.9 million in 2017, and is expected to witness a CAGR of 1.4% over the forecast period (2018 – 2026).

Telmisartan is an angiotensin receptor blocker (ARB) used alone or in combination with other agents for therapy of hypertension, in cardiac arrest, and in stroke management. Telmisartan was approved for use in the U.S., for treatment of hypertension in 1998. Telmisartan is available in 20, 40 and 80 mg tablets in generic forms and under the trade name, Micardis. The typical dose of Telmisartan in adults is 40 to 80 mg once daily, and it is used long term. Telmisartan is also available in fixed combinations with hydrochlorothiazide, and amlodipine.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/2524

Market Dynamics

Prevalence of high blood pressures, is increasing globally attributed to rising geriatric population, chronic disorders such as diabetes, and changing lifestyles which in turn is expected to increase the demand for telmisartan in global market. According to Blood Pressure UK, 2017 update, high blood pressure is the leading cause of heart disease and stroke, killing around 7.5 million people worldwide every year. In 1975, 594 million people were suffering from high blood pressure which increased to 1.1 billion in 2015 and is thought to be due to population growth and an aging population. Thus, rise in geriatric population suffering from high blood pressure is expected to be major factor for growth of telmisartan market in the forecast period.

Furthermore, increasing approvals for Abbreviated new Drug Application (ANDA) for manufacturing of generic telmisartan tablets is propelling growth of telmisartan in the global market. For instance, in July 2014, Glenmark Generics Inc., USA—a subsidiary of Glenmark Generics Limited—received ANDA approval from the U.S. Food and Drug Administration (USFDA) for telmisartan tablets. The Texas Council on cardiovascular disease and stroke works with key players to implement plan for reducing rate of cardiovascular disease and stroke burden in Texas. The plan provides an overview of the current state of cardiovascular disease and stroke in Texas, summary of findings from the heart disease and stroke prevention system assessment, as well as information on mortality, morbidity, prevalence, and related risk factors.

Rising prevalence of hypertension globally is creating disease burden and propelling demand for developing antihypertensive drugs in the global market. For instance, the National Health and Nutrition Examination Surveys (NHANES) provided important epidemiologic information on the prevalence and control of hypertension in the U.S., between 1960 and 2014, which stated that 26 percent of the world's adult population (972 million) was suffering from hypertension in 2000, while number increased by 31 percent (1.39 billion) in 2010, and the number is estimated to reach 1.56 billion by 2025.

Furthermore, increasing marketing approvals for generic versions of telmisartan is expected to propel growth of telmisartan market. For instance, in August 2017, Zydus Cadila received approval from the US FDA to market telmisartan and hydrochlorothiazide tablets, in the strengths of 40mg/ 12.5 mg, 80 mg/12.5 mg and 80mg/25 mg. However, drug shortages are likely to inhibit the growth of the Telmisartan market. For instance in June 2018, US FDA reported shortage of Boehringer Ingelheim Pharmaceuticals, Inc.’s, telmisartan and amlodipine (Twynsta) tablets 80mg/10mg, 30 count blister, due to discontinuation of its business. Moreover, Drug Shortages Canada also reported shortage of Teva- Telmisartan 80mg tablet in Canada, due to lack of complying with good manufacturing practices.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2524

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.